0000899243-20-028806.txt : 20201020 0000899243-20-028806.hdr.sgml : 20201020 20201020200444 ACCESSION NUMBER: 0000899243-20-028806 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201016 FILED AS OF DATE: 20201020 DATE AS OF CHANGE: 20201020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLIAMS DOUGLAS E CENTRAL INDEX KEY: 0001184847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 201249338 MAIL ADDRESS: STREET 1: C/O AMGEN INC STREET 2: ONE AMGEN CENTER DR CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 857-400-4222 MAIL ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-16 0 0001659352 Codiak BioSciences, Inc. CDAK 0001184847 WILLIAMS DOUGLAS E C/O CODIAK BIOSCIENCES, INC. 35 CAMBRIDGEPARK DRIVE, SUITE 500 CAMBRIDGE MA 02140 1 1 0 0 President & CEO Common Stock 2020-10-16 4 C 0 9585 A 9585 D Series C Preferred Stock 2020-10-16 4 C 0 66004 D Common Stock 9585 0 D Each share of Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-6.8855 basis upon the closing of the Issuer's initial public offering on October 16, 2020 and had no expiration date. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. /s/ Yalonda Howze by Power of Attorney for Douglas E. Williams 2020-10-20